Synchron Secures $200 Million to Advance Stentrode Platform Commercialisation
US-based Synchron has raised $200 million in a Series D funding round to support the commercial launch of its Stentrode brain-computer interface (BCI) platform and to develop next-generation interface technology.
Funding Details and Investors
The investment round was led by Double Point Ventures with additional backing from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New participants in this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Purpose of Funding
- Advance commercial rollout of the Stentrode BCI platform
- Accelerate clinical studies
- Expand the interdisciplinary team
- Support development of a next-generation, transcatheter high-channel whole-brain interface
CEO Statement
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
— Tom Oxley, Founder and CEO of Synchron
Synchron's innovation targets improving quality of life for individuals with paralysis by offering a non-invasive, implantable brain interface designed for daily use.
Stay informed with expert analysis to anticipate policy changes and ensure proactive decision-making.
Summary: Synchron's $200 million funding boost accelerates the commercial rollout of its pioneering non-surgical brain-computer interface, aiming to revolutionize treatments for paralysis.